This launch follows the nod from the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA), making Biocon the ...

Biotechnology firm Biocon on Friday said it has launched a product for diabetes and obesity management in the UK.

Bengaluru: Biocon Limited, an innovation-led global biopharmaceutical company, has announced the launch of its GLP-1 peptide, ...

Biocon will market Liraglutide under two brand names - Liraglutide Biocon for diabetes, which is a generic version of Victoza ...

Liraglutide in United Kingdom: Our Bureau, Bengaluru Friday, February 28, 2025, 15:30 Hrs [IST] Biocon Limited, an innovation-led global ...

Biocon announced the launch of its GLP-1 peptide, Liraglutide, for diabetes and obesity, in the United Kingdom (U.K.). The drug-device combination will be marketed in the U.K. under the brand names ...

Biocon launches Liraglutide, a GLP-1 peptide, in the UK for diabetes and obesity management. This marks the first generic ...

Biotechnology firm Biocon on Friday said it has launched a product for diabetes and obesity management in the UK.

Shares of Biocon Ltd took a hit on Friday, February 28, 2025, slipping to a day’s low of Rs 300.10, marking a 3.92 per cent ...

RAs are transforming obesity treatment, demonstrating substantial weight loss and metabolic improvements with lifestyle ...

After the Indian market ended the monthly expiry session on a sour tone, the early Gift Nifty trend on Friday indicated to a ...

Artificial intelligence tools continue to be a focal point among publicly traded digital health companies looking to improve ...